Gilead acquiring Nimbus' NASH subsidiary

Gilead Sciences Inc. (NASDAQ:GILD) is acquiring the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics LLC (Cambridge, Mass.) for $400 million up front and up to $800 million in development milestones.

The deal gives Gilead a portfolio of acetyl-coenzyme A carboxylase ( ACAC; ACC) inhibitors for liver diseases including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Data from a Phase I study of lead program NDI-010976 are to be presented next month at the European Association for the Study of the Liver (EASL) meeting. The compound received Fast Track designation from FDA in February. The rest of the assets are in preclinical development. ...